Sai Parenterals Limited has informed the Exchange about Investor Presentation
SAIPARENT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sai Parenterals Limited released its Q4 and FY26 investor presentation. FY26 standalone revenue grew 31% YoY to ₹162 crore, with EBITDA up 23% at ₹33 crore and PAT surging 64% to ₹17 crore. Consolidated FY26 revenue stood at ₹381 crore including its newly acquired Australian subsidiary Noumed (acquired November 2025). CDMO revenue surged over 250% YoY, driven by deeper customer engagement. The company expanded its portfolio by 93 dossiers in FY26 and has 67 dossiers under development for future growth. The company completed its IPO in March 2026 raising ₹285 crore and listed on BSE and NSE in April 2026. Capacity expansion at injectables units is underway with EU-GMP upgradation expected by January 2027.
The strong standalone performance and 250% CDMO revenue growth signal robust business momentum. The disclosed order pipeline of 67 dossiers under development provides multi-year revenue visibility. The ongoing capacity expansion and EU-GMP upgrades position the company for deeper penetration in regulated markets.